Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2008;336:629-630 (22 March), doi:10.1136/bmj.39520.483565.3A
| The first 150 words of the full text of this article appear below. |
Instead of speculating about our differing methods as the source of our differing conclusions, Turner and Rosenthal instead focused on our adoption of UKs National Institute for Health and Clinical Excellence (NICE) criteria for clinical significance. NICE adopted Cohens definition of a "medium" effect size (0.5) for clinical significance.1 2 Cohen intended that a medium effect size represent an effect of a size likely to be visible to the naked eye of a careful observer (p 156). By this interpretation, clinical significance of antidepressants is reached when a careful observer can see that medicated patients have noticeably lower depression than patients taking placebo. In this light, the NICE criteria seem sensible indeed.
A more appropriate use of Turner and Rosenthals "d-juice" metaphor (where d-juice is the level of antidepressant efficacy) to explain our findings is that the amount of d-juice in the trials was pitifully small or even non-existent when people
Irving Kirsch, professor of psychology, Blair T Johnson, professor of psychology
1 University of Hull, Hull HU6 7RX, 2 Department of Psychology and Center for Health, Intervention, and Prevention, University of Connecticut, Storrs, Connecticut, USA
I.Kirsch@hull.ac.uk